SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease

Exclusion Criteria16

• Patients who have HBV, HCV, and other acquired and congenital immunodeficiency diseases.
• Patients who have grade 2 or higher of peripheral neuropathy or neuralgia according to the definition of NCI CTCAE version 4.0.
• Plasma cell leukemia.
• Serious thrombotic events.
• Active, unstable cardiovascular dysfunction: a. symptomatic ischemia; b. Uncontrolled, clinically significant conduction abnormalities (except antiarrhythmic ventricular tachycardia), but patients with first-degree atrioventricular block or asymptomatic left anterior bundle/right fascicular block cannot be excluded. c. New York Heart Association (NYHA) Class III - IV or left ventricular ejection fraction (LVEF) \<40%; d. Myocardial infarction Within 3 months before C1D1.
• Significant hepatic dysfunction (ALT and AST ≥ 3 times the upper limit of normal (ULN)).
• Serum bilirubin≥1.5 × ULN.
• creatinine clearance \<30 ml/min.
• History of active malignancy during the past 5 years with the exception of basal carcinoma of the skin or stage 0 cervical carcinoma.
• Previous major operation within 30 days before C1D1.
• Patients who have epilepsy, dementia requiring medication, or other mental disorders who are unable to understand or adhere to the study protocol.
• According to the study protocol or in the opinion of the investigator,serious physical or mental illness that is likely to interfere with the study procedures/results.
• Any psychological, familial, sociological and geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
• Current participation in another clinical trial.
• Pregnant or lactating women.
• Patients with other commodities that the investigators considered not suitable for the enrollment.